Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial
| dc.contributor.author | Ahmed Bolad | |
| dc.date.accessioned | 2017-08-27T08:06:34Z | |
| dc.date.available | 2017-08-27T08:06:34Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | The glutamate-rich protein (GLURP) of P. falciparum is the target of cytophilic antibodies which are significantly associated with protection against clinical malaria. A phase 1 clinical trial was conducted in healthy adult volunteers with the long synthetic peptide (LSP) GLURP85–213 combined with either Aluminum Hydroxide (Alum, 18 volunteers) or Montanide ISA 720 (ISA, 18 volunteers) as adjuvants. Immunizations with 10, 30 or 100μg GLURP85–213 were administered subcutaneously at days 0, 30, and 120. Adverse ... | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/4917 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartofseries | Volume 25;Issue 15, Pages 2930-2940 | |
| dc.subject | Malaria | en_US |
| dc.subject | Plasmodium falciparum | en_US |
| dc.subject | GLURP | en_US |
| dc.subject | Immunization | en_US |
| dc.title | Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial | en_US |